This Plain Language Summary of Publication article (PLSP) from Future Oncology, presents the long-term results from the JAVELIN Bladder 100 study, which examined whether avelumab maintenance treatment, combined with supportive care, helps people with advanced urothelial cancer live longer compared to supportive care alone. The study found that avelumab significantly extended survival for patients whose cancer had shrunk or stopped growing after first-line chemotherapy. The long-term results confirmed that avelumab continued to help patients live longer, establishing it as the standard treatment for advanced urothelial cancer after chemotherapy.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up’ and was published in the Journal of Clinical Oncology.

Visit ASCO Publications using the link to read the original article.